Page last updated: 2024-12-11

azodicarbonamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5462814
CHEMBL ID28517
CHEBI ID156571
MeSH IDM0045615

Synonyms (114)

Synonym
azodicarboxamide
azobiscarbonamide
azobiscarboxamide
lucel ada
azodicarboamide
porofor 505
genitron ac 2
123-77-3
1,1'-azobiscarbamide
uniform az
nsc41038
formamide,1'-azobis-
celogen az 130
porofor dhkhz 21
genitron ac 4
.delta.1,1'-biurea
nsc-41038
porofor chkhz 21r
celogen az 199
kempore r 125
chkhz 21
1,1'-azodiformamide
yunihomu az
unifoam az
celosen az
pinhole ak 2
1,1'-azobis[formamide]
azobisformamide
azodiformamide
kempore 125
.delta.(1,1')-biurea
porofor chkhz 21
celogen az
nci-c55981
porofor adc/r
ln: zvnunvzy
genitron ac
azodicarbamide
pinhole acr 3
azodicarboxylic acid diamide
chkhz 21r
azodicarbonamide
diazenedicarboxamide
abfa
ficel ep-a
(e)-diazene-1,2-dicarboxamide
nsc-674447
NCGC00091844-01
kempore
nitropore
nsc 41038
poramid k 1
delta(1,1')-biurea
hsdb 1097
1,1'-azobis(formamide)
genitron epc
kempore 60/40
porofor-lk 1074 (bayer)
einecs 204-650-8
un3242
nsc 674447
c,c'-azodi(formamide)
ai3-52516
ccris 842
unifoam azh 25
formamide, 1,1'-azobis-
1,1'-azobisformamide
carbamoyliminourea
nsc674447
azodicarboxamide, 99%, fcc
azodicarboxamide, 97%
e927a
CHEMBL28517
CHEBI:156571
(e)-carbamoyliminourea
A805148
NCGC00091844-03
NCGC00091844-02
tox21_303264
cas-123-77-3
dtxcid104553
NCGC00257169-01
dtxsid0024553 ,
NCGC00259398-01
tox21_201849
A0567
AKOS006223494
diazene-1,2-dicarboxamide
56z28b9c8o ,
1,2-diazenedicarboxamide
unii-56z28b9c8o
ec 204-650-8
azodicarbonamide [un3242] [flammable solid]
AM20080172
S2430
1,1'-azobis(formamide) [hsdb]
azodicarbonamide [fcc]
azodicarbonamide [mi]
(e)-(carbamoylimino)urea
J-519624
azodicarboxamide, analytical reference material
azm 2s
vinyfor
azobis ca 51c
azocel
azoplastone
azoform a
azobis ca 110b
evipor
paramid k1
mfcd00007958
bdbm50455377
(carbamoylimino)urea
EN300-7590294

Research Excerpts

Overview

Azodicarbonamide (ADA) is a dough enhancer currently used as a replacement for potassium bromate in the process of bread-making in countries such as Nigeria. It is a low molecular weight foaming agent for plastics and rubbers.

ExcerptReferenceRelevance
"Azodicarbonamide is a dough-enhancer used in the process of breadmaking in countries like Nigeria. "( An Assessment of the Effects of Azodicarbonamide-containing Diet on Neurobehaviour, Brain Antioxidant Status and Membrane Lipid Peroxidation Status in Rats.
Adeyeba, A; Olofinnade, AT; Onaolapo, AY; Onaolapo, OJ, 2020
)
2.28
"Azodicarbonamide (ADA) is a dough enhancer currently used as a replacement for potassium bromate in the process of bread-making in countries such as Nigeria. "( Food-added azodicarbonamide alters haematogical parameters, antioxidant status and biochemical/histomorphological indices of liver and kidney injury in rats.
Adeyeba, OA; Olofinnade, AT; Olowe, OA; Onaolapo, AY; Onaolapo, OJ, 2020
)
2.39
"Azodicarbonamide is a low molecular weight foaming agent for plastics and rubbers. "( Occupational asthma due to azodicarbonamide.
Cho, JH; Hong, YC; Kim, CW; Lee, HL; Leem, JH; Ryu, JS, 2004
)
2.06
"Azodicarbonamide is a medium temperature blowing agent used in the production of foamed polymers. "( Development and use of a sampling and analytical method for azodicarbonamide.
Ahrenholz, SH; Neumeister, CE, 1987
)
1.96

Effects

ExcerptReferenceRelevance
"Azodicarbonamide has been banned or limited in many countries. "( Application of Visible/Near-Infrared Spectroscopy in the Prediction of Azodicarbonamide in Wheat Flour.
Che, W; Dai, C; Sun, L; Tan, W; Wang, L; Ye, D; Zhang, D; Zhang, Q, 2017
)
2.13

Toxicity

ExcerptReferenceRelevance
" Based on estimates of exposure to infants consuming baby foods (with the assumption of SEM levels at the 95th percentile of 20 ng g(-1) in all of the consumed 'ready-to-eat' foods) compared with a no observed adverse effect level (NOAEL) in developmental toxicity studies, the margin of safety is more than 21 000."( Safety assessment and risk-benefit analysis of the use of azodicarbonamide in baby food jar closure technology: putting trace levels of semicarbazide exposure into perspective--a review.
Cheng, E; Goodfellow, GH; Haighton, LA; Lee-Brotherton, VM; Lynch, BS; Musa-Veloso, K; Nestmann, ER, 2005
)
0.57

Bioavailability

ExcerptReferenceRelevance
" These positive attributes can help development of smaller, high drug-loaded dosage forms having enhanced bioavailability and better patient compliance."( Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs.
Azad, M; Bhakay, A; Bilgili, E; Dave, R, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
"The maximal tolerated dosage of ADA appears to be 2 g (three times daily)."( Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy.
Bogner, JR; de Clercq, E; Goebel, FD; Hemmer, R; Margery, H; Pannecouque, C; Schmit, JC; Tassignon, JP; Valeyev, R; Vandevelde, M; Witvrouw, M, 2001
)
0.54
" These positive attributes can help development of smaller, high drug-loaded dosage forms having enhanced bioavailability and better patient compliance."( Redispersible fast dissolving nanocomposite microparticles of poorly water-soluble drugs.
Azad, M; Bhakay, A; Bilgili, E; Dave, R, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (44 Product(s))

Product Categories

Product CategoryProducts
Other19
Cariñena1
Desserts, Frozen foods, Frozen desserts2
Plant-based foods and beverages, Plant-based foods, Dried products, Pastas, Dried products to be rehydrated, Noodles, Instant noodles1
Snacks, Snacks sucrés, Biscuits et gâteaux, Pâtisseries, Meringues1
Snacks, Sweet snacks, Biscuits and cakes, Biscuits1
Snacks, Snacks sucrés, Biscuits et gâteaux, Gâteaux, Cakes aux fruits1
Plant-based foods and beverages, Plant-based foods, Prepared vegetables, Baked beans in tomato sauce1
Cibi e bevande a base vegetale, Cibi a base vegetale, Pasta1
Kasvipohjaiset ruoat ja juomat, Kasvipohjaiset ruoat, Aamupalat, Levitteet, Kasvipohjaiset levitteet, Makeat levitteet, Hedelmäsäilykkeet, Marmeladit1
Aliments et boissons à base de végétaux, Aliments d'origine végétale, Fruits à coques et dérivés, Fruits à coques, Amandes, Amandes effilées1
Plant-based foods and beverages, Beverages, Plant-based beverages, Carbonated drinks, Fruit-based beverages, Sodas, Fruit sodas, Orange soft drinks, Sweetened beverages1
Toastbrote1
Juomat, Vedet, Lähdevedet, Kivennäisvedet1
Plats préparés, Plats à base de pâtes, Plats préparés au poisson, Lasagnes préparées, Lasagnes au poisson, Plats au saumon, Lasagnes au saumon1
Snacks, Sweet snacks, Cocoa and its products, Confectioneries, Chocolate candies1
Snacks, Snacks sucrés, Confiseries, Bonbons, Bonbons français, Bêtises de Cambrai1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Fromages, en:cooked-pressed-cheeses, Fromages de France, Comté, en:aoc-cheeses, en:labeled-cheeses1
Produits laitiers, Produits fermentés, Produits laitiers fermentés, Crèmes, Crèmes épaisses, Frais, Crèmes entières, Crèmes épaisses entières, Crème Fraîche d'Isigny, Crèmes fraîches1
Seafood, Fishes and their products, Canned foods, Fishes, Fatty fishes, Canned fishes, Tunas, Canned tunas, en:tuna-chunks1
Getränke, Alkoholische Getränke, Biere, Lager, Pilsners1
Supplementi dietetici, Integratori per bodybuilding, Barrette proteiche1
Fertiggerichte, Fertigsalate, Salatmischung, en:salads1
Condimentos, Salsas, Salsas de chiles, en:groceries1
Flavoured double cream yogurt1

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Fudge Striped CookiesBack To NatureSnacks, Sweet snacks, Biscuits and cakes, Biscuitsammonium bicarbonate2024-06-19
Sugar free lotta popsNorth StarDesserts, Frozen foods, Frozen dessertssorbitol2024-02-09
Double greek yogurt Lemon meringue flavouredSundaleFlavoured double cream yogurtNatamycin2024-02-14

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency6.30720.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency6.30720.025120.237639.8107AID886; AID893
LuciferasePhotinus pyralis (common eastern firefly)Potency28.49680.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency51.29110.002541.796015,848.9004AID1347395; AID1347397; AID1347398
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency0.44670.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency30.73140.003041.611522,387.1992AID1159552; AID1159555
estrogen nuclear receptor alphaHomo sapiens (human)Potency0.39010.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency54.94100.001019.414170.9645AID743191
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency10.00000.001815.663839.8107AID894
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.12590.010039.53711,122.0200AID588547
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.38930.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency47.30790.000627.21521,122.0200AID651741
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency11.22020.00798.23321,122.0200AID2551
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency31.62280.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency31.62281.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histone-lysine N-methyltransferase EHMT2Homo sapiens (human)IC50 (µMol)0.50000.00251.14809.2000AID1374899
Histone-lysine N-methyltransferase EHMT1Homo sapiens (human)IC50 (µMol)1.70000.01300.79954.9000AID1374900
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (26)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to starvationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of DNA replicationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
synaptonemal complex assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
spermatid developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
long-term memoryHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
fertilizationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
regulation of protein modification processHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
organ growthHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
phenotypic switchingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
behavioral response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
oocyte developmentHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
neuron fate specificationHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to cocaineHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
cellular response to xenobiotic stimulusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of autophagosome assemblyHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
DNA methylation-dependent heterochromatin formationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
regulation of embryonic developmentHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
response to fungicideHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
positive regulation of cold-induced thermogenesisHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
RNA polymerase II transcription regulatory region sequence-specific DNA bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
enzyme bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K56 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
promoter-specific chromatin bindingHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
transcription corepressor bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
zinc ion bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K27 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
C2H2 zinc finger domain bindingHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
histone H3K9me2 methyltransferase activityHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nuclear speckHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT2Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nuclear bodyHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
chromatinHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase EHMT1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (11)

Assay IDTitleYearJournalArticle
AID1374900Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374897Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID235381Therapeutic index (EC50 / CC50) was evaluated1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.
AID1374901Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374895Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID81104Compound concentration that provides 50% cytoprotection on CEM-SS cells and HIV-1RF was measured using XTT assay.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.
AID1374899Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID81061CC50 reflects the drug concentration that elicits 50% cell death of CEM-SS cells and HIV-1RF was measured using XTT assay.1998Journal of medicinal chemistry, Apr-23, Volume: 41, Issue:9
Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins.
AID1374896Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374902Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374898Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit2018Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7
Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (22.95)18.7374
1990's8 (13.11)18.2507
2000's15 (24.59)29.6817
2010's19 (31.15)24.3611
2020's5 (8.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 58.71

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index58.71 (24.57)
Research Supply Index4.20 (2.92)
Research Growth Index4.70 (4.65)
Search Engine Demand Index95.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (58.71)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.54%)5.53%
Reviews5 (7.69%)6.00%
Case Studies7 (10.77%)4.05%
Observational0 (0.00%)0.25%
Other52 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]